

**HEPATITIS B SEROLOGICAL MARKERS AND RISK FACTORS AMONG
PREGNANT WOMEN AND PROSPECTIVE BLOOD DONORS IN SOUTHWESTERN
NIGERIA**

Running Title: HBV markers and risk factors in south western Nigeria

Abstract

Background: Hepatitis B control, especially among pregnant women and prospective blood donors, in the developing world is still a disease that must be given attention considering its mortality and morbidity rates.

Method: This study was conducted among 153 subjects including pregnant women and prospective blood donors using appropriate hepatitis B serological marker ELISA kits (WANTAI, China) for each marker.

Results: Among the subjects screened, 38 had at least one of the markers. Among those that showed no detectable HBsAg were 2 prospective blood donors with HBeAg and another 6 prospective blood donors and 2 pregnant women with HBcAb-IgM detected in them all indicating an ongoing infection and replication of hepatitis B virus. Sexual activities were found to be of statistical significance in the study.

Conclusion: It is imperative to give more attention to control of HBV spread through more sex education and administration of vaccination.

Keywords: Pregnant, blood donor, HBV, markers, sexual activities

22 **Introduction**

23 Hepatitis B virus (HBV) infection is a serious public health problem causing most of the acute
24 and chronic liver disease [1]. It is estimated globally that 2 billion people (approximately 30% of
25 the world population) have HBV infection, of which 300-400 million have chronic infection [2,
26 3]. About 5% of the world population are at risk of developing chronic infection leading to 5
27 million to 1.2million death yearly [4, 5]. The causative agent is a member of the family
28 Hepadnaviridae and belongs to Orthohepadnavirus genus. HBV invades the liver and causes
29 acute hepatitis which may resolve without complication but in some cases may lead to chronic
30 form of the disease [6].

31 HBV infection is highly infectious and can be transmitted covertly by percutaneous routes and
32 overtly by blood transfusion [3]. Transfusion transmitted hepatitis B infection (TTHBVI) has
33 always been a dreaded disease with an increased incidence in donated blood [7]. The use of
34 unscreened blood transfusion keeps the patient at a high risk of acquiring such transfusion
35 transmitted infection (TTI) [3]. Screening for serological markers (viral antigens and host
36 antibodies) helps to establish a suspected HBV infection from different phases of the chronic
37 disease and also the severity of the infection [8, 9]. The serological markers of hepatitis B virus
38 infection are hepatitis B surface antigen (HBsAg), and its corresponding antibody, (antiHBs),
39 hepatitis B core antigen (HBcAg), and antibodies to the core antigen (antiHBc- IgM and IgG),
40 hepatitis B envelope antigen (HBeAg), and hepatitis B envelope antibody (antiHBe) and
41 hepatitis B virus DNA (HBV DNA) [1]. HBV DNA can be detected very early after HBV
42 infection and it generally indicates active viral replication. HBsAg is the first serological marker
43 to appear during incubation period and can initially be detected in serum from 1-12weeks after

infection. During convalescence, it declines to undetectable levels and if it persists for more than 6months then it indicates a carrier state and a risk for chronic hepatitis.

The discovery of HBsAg was a major breakthrough in decreasing the incidence of transfusion transmitted hepatitis B. However, in many developing countries, including Nigeria, screening of blood before transfusion for HBsAg alone is still in practice in the prevention of HBV transmission during blood transfusion [10]. The screening of donated blood by enzyme-linked immunosorbent assay (ELISA) is the common method used for the detection of the viral marker. HBsAg screening however does not totally rule out the risk of transmission of hepatitis B [11, 12]. This is because during serological response of the host to infection, there is a phase called the ‘window period’ in which HBsAg cannot be detected in the blood. The window period represents a carrier state of the disease although the infection is present. During the window period, when the HBsAg has disappeared and HBsAb has not yet appeared, the detection of the antibody to the hepatitis B core antigen serves as a useful serological marker for HB infection [13]. The IgM class of the anti-HBc is the first to appear indicating recent infection while the IgG variety of anti-HBc appears later during infection and shows a previous HBV infection [11].

Individuals with IgG variety of anti-HBc may not be infectious as they may have sufficiently high titres of antibodies to HBsAg which are protective in nature and the affected individuals may actually be disease free [7, 11]. It has been demonstrated that some patients with no detectable HBsAg in them but showing HBc IgM antibody in their sera continue to replicate HBV [14]. Thus, the absence of HBsAg in the blood sample may not be enough to prove absence of an ongoing HBV infection. Blood containing anti-HBc (IgM) with or without detectable presence of HBsAg might be infectious, therefore routine prospective blood donor screening for anti-HBc (IgM) may be necessary to decrease the risk of transfusion transmitted hepatitis B. This

study was designed to determine the prevalence of HBV serological markers and the risk factors associated with HBV transmission in Southwestern Nigeria among blood donors and pregnant women.

Materials and Methods

Study population and location

A total of 153 participants (Male/Female: 67/ 86) were enrolled in the study. All the females were pregnant women while the males were prospective blood donors, recruited from private and government hospitals in Osun, Oyo and Ondo states, all in the Southwestern Nigeria. The samples were collected from September 2015 to January 2016.

Sample collection and Preparation

Three milliliters (3ml) of venous blood was collected into sterile plain bottles from each patient, centrifuged at 3000rpm for 10 minutes and the serum transferred aseptically into labelled cryovials. The sera were stored at -20°C until analysed. The sociodemographic and risk factors data were collected using structured questionnaire.

Serological Testing

All samples were tested for HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc (total and IgM), using ELISA (Wantai AiDTM, Wantai Biopharmaceuticals, China) according to manufacturer's instruction. The subjects who tested positive to the markers were compared in terms of gender, age group and risk factors by use of chi-square and Fisher's exact test at 95% confidence interval, using SPSS version 20.0.1 for Windows.

Results

Prevalence of Hepatitis B Virus serological markers in South-western Nigeria

The occurrence of all the serological markers, except HBeAg, detected in the study population were relatively high with at least one serological marker detected in 24.8% (n=38) of the study population. Specifically, the prevalence of the markers HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc (total) and HBcIgM detected in the 153 samples are respectively 19(12.4%), 21(13.7%), 3(2.0%), 20(13.1%), 52(34.0%), 14(9.2%).

Socio-demographic data and Study Location of samples positive for HBV serological Marker

Table 1 shows the distribution of the detectable HBV markers according to the socio-demographic data, study location and months of sample collection and their levels of significance.

Table1: Socio-Demographic Parameter and Prevalence of Hepatitis B Markers in screened individuals

Sociodemographic parameter		Samples positive for HBV Serological Markers (%)						
		HBsAg (%)	HBsAb (%)	HBeAg (%)	HBeAb (%)	HBcAb (Total) (%)	HBcAb-IgM (%)	P value (95% CI)
Sex	Male	8 (12)	9 (13.4)	2(3)	11(16.4)	29 (43.3)	8(12)	
	Female	11(12.8)	12(14)	1(1.1)	9 10.5)	23(26.7)	6(7)	
	Total	19	21	3	20	52	14	
Marital Status	Single	4 (7.4)	6(11.1)	1(1.9)	7(13)	20(37)	5 (9.3)	
	Married	15 (15.2)	15 (15.2)	2 (2.0)	13(13.1)	32 (32.3)	9 (9.1)	
	Total	19	21	3	20	52	14	
Age	11-20	1(25)	2(50)	0(0)	0 (0)	1(25)	0 (0)	0.529
	21-30	8 (9.3)	13 (15.1)	1 (1.2)	9 (10.5)	30 (34.9)	8 (9.3)	
	31-40	9 (18)	3 (6)	1 (2)	9 (18)	14 (28)	4 (8)	
	41-50	1 (9.1)	2(18.2)	0 (0)	2 (18.2)	7 (63.7)	1 (9.1)	
	51-60	0 (0)	1 (100)	1 (100)	0 (0)	0 (0)	1 (100)	
	Total	19	21	3	20	52	14	
Occupation	Civil Servant	2 (7.1)	3 10.7)	1 (3.6)	2 (7.1)	13 (46.4)	3 (10.7)	0.754
	Trading	7 (21.9)	4 (12.5)	0 (0)	7 (21.9)	11	2 (6.3)	
	Artisan	6 (12.8)	5 (10.6)	1 (2.1)	6 (12.8)	14 (29.8)	5 (10.6)	
	Housewife	0 (0)	1 (16.7)	0 (0)	0 (0)	1 (16.7)	0 (0)	
	Bank Staff	0 (0)	1 (25)	0 (0)	1 (25)	3 (75)	0 (0)	
	Students	4 (14.3)	6 (21.4)	1 (3.6)	4 (14.3)	8 (28.6)	4 (14.3)	
	Others	0 (0)	1 (12.5)	0 (0)	0 (0)	2 (25)	0 (0)	
	Total	19	21	3	20	52	14	
State	Ondo	10 (20.8)	7 (14.6)	0 (0)	11 (22.9)	26 (54.2)	4 (8.3)	0.082
	Osun	7 (10.1)	9 (13.0)	3 (4.3)	8 (11.6)	26 (37.7)	8 (11.6)	
	Oyo	2 (5.6)	5 (13.9)	0 (0)	1 (2.8)	-(0)	2 (5.6)	

	Total	19	21	3	20	52	14	
Months of Collection	September	1 (2.6)	2 (5.3)	1 (2.6)	4 (10.5)	17 (44.7)	5 (13.2)	
	October	3 (8.8)	6 (17.6)	0 (0)	4 (11.8)	16 (47.1)	2 (5.9)	
	November	11(21.2)	8 (15.4)	1 (1.9)	10 (19.2)	17 (32.7)	5 (9.6)	
	December	1 (25)	1 (25)	0 (0)	0 (0)	-(0)	0 (0)	
	January	3 (20)	4 (26.7)	1 (6.7)	2 (13.3)	2 (13.3)	2 (13.3)	
	Total	19	21	3				

Out of the 69 prospective blood donor samples that showed no detectable HBsAg, 2(1.5%; 2/134) had HBeAg in them indicating active HBV replication. One of these two prospective blood donor had anti-HBcIgM, showing recent infection while the other is negative for all other markers tested. The distribution and occurrence of other HBV serological markers in HBsAg negative subjects is as shown below

Table 2: Other Hepatitis B Virus serological markers in HBsAg Negative Individuals

	HBsAg +ve	HBsAg -ve	HBsAg -ve & HBeAg +ve	HBsAg -ve & HBcAb +ve	HBsAg -ve & HBcAb-IgM +ve
Blood Donors	9	69	2	27	6
Pregnant Women	10	65	0	13	2
Total	19	134	2	40	8

Table 3: Detailed serological profile of HBsAg Negative but HBcIgM positive samples

S/N	Lab ID	Age Group	Sex	State	Marital Status	Group	Occupation	HBsAb	HBcAb Status	HBeAg Status	HBeAb
1	A003	21-30	Male	Osun	Single	Blood Donor	Student	Negative	Positive	Negative	Negative
2	A006	>60	Male	Osun	Married	Blood Donor	Civil Servant	Positive	Negative	Positive	Negative
3	A017	41-50	Male	Osun	Married	Blood Donor	Civil Servant	Negative	Positive	Negative	Positive
4	A036	21-30	Male	Osun	Single	Blood Donor	Student	Negative	Positive	Negative	Negative
5	A037	21-30	Male	Osun	Single	Blood Donor	Artisan	Negative	Positive	Negative	Negative
6	IB013	21-30	Female	Oyo	Married	Pregnant	Artisan	Positive	Negative	Negative	Negative
7	MC006	21-30	Female	Osun	Single	Blood Donor	Student	Negative	Positive	Negative	Negative
8	S008	21-30	Female	Oyo	Married	Pregnant	Artisan	Negative	Negative	Negative	Negative

115 Serological Marker and Risk Factors of HBV Transmission

116 Table 4 shows the risks factors associated with HBV transmission and the serological markers.

117 There was no correlation between history of blood transfusion, occupation, surgery, dental
 118 extraction, tattoo, sharing sharps and prevalence of HBsAg ($P = 0.05$). However, there were
 119 significant correlation between sexual activity, number of sex partners, use of protection during
 120 sexual activity and HBsAg prevalence ($P=0.03$, 0.04 and 0.02 respectively). There was no
 121 correlation between HBV vaccine record and the distribution of the markers as many of the
 122 subjects could not ascertain their vaccination history.

123 The table below shows the significance values obtained for some of the risk factors considered

124 Table 4: The Risk factors associated with HBsAg distribution and the P values at 95% CI

Risk Factors	P Values	125
Occupation	0.75	
Marital Status	0.15	
Blood transfusion	0.51	
Surgery	0.90	
Hospital Admission	0.95	
Dental Surgery/Extraction	0.93	
Sexual Activity	0.02**	
Number of sex Partners	0.04**	
How often you have sex	0.02**	
Protective measures in sex	0.02**	
Use/share of Sharps	0.07	
Tattoo	0.37	
Family member diagnosed of HB	0.18	

126 Note: ** show significant values at 95% CI

127

128 Discussion

129 High prevalence of serological markers of HBV is reported in the study population, except for
 130 HBeAg which shows a prevalence of 2%. The prevalence of HBsAg and its corresponding
 131 antibody in this study was 12.4% and 13.7% respectively. In Nigeria the prevalence of HBsAg
 132 ranges from 2.4% to 19.6% [15 – 18], depending on the study population while anti-HBs

prevalence is between 2.5 to 35% [15, 19, 20]. Hepatitis B e antigen and its associated antibody (HBeAb) has been found among different population to be between 1.5% -16.2% and 23% -81% respectively [21, 19, 17, 20] while antiHBc total and HBcIgM values are between 32%-67% and 4% to 18.4% respectively [15, 16, 21, 19, 20]. The prevalence of the serological markers observed in this study falls within the range reported in previous studies above.

Laboratory detection of hepatitis B virus infection is crucial for global control and prevention of HBV disease. Previous studies have suggested that performing HBsAg tests alone does not completely eliminate the risk of HBV transmission to blood recipients [7, 11, 12, 22]. This study reports the presence of HBeAg (1.5%; 2/134) and HBcIgM (6.0%; 8/134) in the absence of HBsAg. These markers correspond to viral replication and recent HBV infection. The progression of liver disease in hepatitis B virus (HBV) infection is being fostered by active virus replication [23] and the presence of hepatitis B e antigen (HBeAg) in the serum generally indicates ongoing viral replication, disease progression and infectivity [24 – 27] hence HBeAg positive patients have high levels of serum HBV-DNA which indicates extremely intensive viral replication [24]. Transfusion of blood from the two HBeAg positive donors on the basis of HBsAg negativity as done in many developing countries including Nigeria is unsafe and will most likely result in post transfusion HBV infection since the donors are actively replicating the virus.

Anti-HBc (total) indicates history of infection whether present or past [22, 28] while HBcIgM is a marker of recent HBV infection. Although the detection of HBV DNA was not carried out in this study to detect Occult HBV infection (OBI), the detection of anti-HBc in the serum of HBsAg-negative individuals is recognized as a marker of exposure or as being suggestive of occult infection [29 - 31, 22]. In this study, we found the prevalence of HBsAg negative but anti-

HBc (total) positive patients to be 29.9% (40/134) while 6.0% (8/134) are recent infection (HBcIgM positive). Interestingly, one of these samples shows HBcIgM as the only marker of HBV infection. Previous studies have suggested screening blood donors for HBcIgM in addition to HBsAg [15, 20] as a way of preventing transmission of HBV through improperly screened blood.

In developed countries, the risk of transfusion-transmitted viral infections have been almost eliminated by the use of questionnaires to exclude donors at higher risk for HIV/HBV infection (donor selection) and the use of highly sensitive laboratory screening tests to identify infected blood donations. On the other hand, effective blood screening and banking system have remained elusive in most developing countries. From this study, there was a correlation between HBsAg and sexual activity as well as the number of sex partners. Blood donors who are sexually active, who have more than one sex partner and who had sex without protection were found to be more infected with HBsAg than their counterparts; use of donor selection could have excluded these prospective blood donors.

In patients with acquired immunity to HBV infection through vaccination, anti-HBs is the only serological marker detected in serum. We found 8 (5.2%) patients who have acquired immunity to HBV probably by vaccination while another five have developed immunity through exposure to the wild virus since they have anti-HBc in addition to the anti-HBs. This result shows that the rate of HB vaccination among the blood donor is low, hence the need for more enlightenment programs of HB vaccine and its benefits. It should be noted that proper HBV vaccination records of many of the subjects could not be confirmed thereby preventing a true picture of the source(s) of the immunity that some of them had acquired. The rate of acquired immunity through vaccination could be said to be low in the study population and we found HBeAg and HBcIgM separately as the only evidence of HBV infection in the population.

Although this study was not designed to identify occult HB infection and HBV genotypes in circulation in the study areas, further studies with larger sample size would attend to this and hence produce fuller information not only on selected markers but on the virus as a whole. However, the study has provided useful information on HBV serological markers, HBV transmission and risk factors in the study area and population. It further buttressed the possibility of being transfused with HBV infected blood if the prospective blood donors are screened for HBsAg only. This should be extended to pregnant women as could be seen in this study of a woman who was HBsAg negative yet carrying the HBcIgM antibody and presenting with signs of ongoing fresh HBV infection

To conclude, sexual activities and the number of sex partners were implicated by this study as routes of transmission, it is therefore important to educate the people in the areas on the importance of abstinence and /or faithfulness to one partner. Public enlightenment program on benefits of HBV vaccine and the need to properly keep records of vaccination is also important. Making HBV vaccination compulsory for women before pregnancy will help prevent vertical HBV and protect the neonates from HBV infection. This study advocates the use of donor selection through the use of questionnaire. The use of HBsAg as the only marker of HBV infection among blood donors should be discouraged while the government should make personnel and facilities available for the screening for other HBV serological markers and not only HBsAg.

Compliance with Ethics guidelines:

Additional informed consent was obtained from all patients for which identifying information is included in this article

205 **Competing Interest**

206 Authors declare that there is no competing interest

207

208

209

210 **References**

211

212 1. Thaer Kadhim Fayyadh and Fuying MA 2017. Comparative study of HBV, HCV and
213 HDV Serological markers among acute hepatitis B, chronic hepatitis B, apparently
214 healthy patients: IOSR Journal of Nursing and health science (e. ISSN;2320-1959),
215 Vol6;pp79-85

216

217 2. Dhawan HK, Marwaha N, Sharma RR, Chawla Y, Thakral B, Saluja K, Sharma SK,
218 Thakur MK, Jain A 2008. Anti-HBc screening in Indian blood donors: Still an unresolved
219 issue. World J. Gastroenterol. 14(34):5327-5330.

220

221 3. Lavanya V., T. Viswanathan, S. Arul Sheeba Malar, A. Malarvizhi and K. Moorthy 2012
222 Prevalence of hepatitis B virus infection among blood donors with antibodies to hepatitis B
223 core antigen Int. J. Med. Med. Sci

224 4. Ibtiha Hameed Mohsin Al-Ezzi and Ansam Dawod Salman 2017 Study of Some Serological
225 Markers (Hbs Ag, Anti-Hbs and Anti-Hbc IgM) for Detection of Occult Hepatitis B Virus
226 Infection Among Blood Donors in Diyala Province. IOSR Journal of Pharmacy and
227 Biological Sciences (IOSR-JPBS) e-ISSN: 2278-3008, p-ISSN: 2319-7676. Volume 12,
228 Issue 1 Ver. I (Jan. - Feb.2017), PP 18-21.

229 5. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM 2009. Management
230 of hepatitis B; National institute of health consensus development conferences statement.
231 Ann Intern Med 150:104-10.

- 232 6. Wasmuth JC 2009. Hepatitis B-epidemiology, transmission and natural history. In
233 Hepatology – A Clinical Text Book; 2nd edition, pp 25-36. Edited by Mausse S, Berg T,
234 Rochstoh J, Sarrazin C, Wedemeyer H. Flying publisher, Germany.
- 235 7. Kumar H, Gupta PK, Jaiprakash M 2007. The role of anti-HBc IgM in Screening of
236 Blood Donors. Med J Armed Forces India (*MJAFI*). 63(4):350-352.
- 237 8. Salawu, L.; Adegoke, A.; Aboderin, A. and Huraina, H. 2011. Hepatitis B viral markers
238 in surface antigen negative blood donors: the need to look beyond antibody negativity.
239 West Afr. J. Med. 30(4): 292-5.
- 240 9. Nna, E.; Mbamalu, C. and Ekejindu, I. 2014. Occult HBV infection among blood donors
241 in South-Eastern Nigeria. Pathog. Glod. Health. 4:204-144.
- 242 10. Olotu A. Amadin, Adesola O. Oyelese, Lateef Salawu, Rosemary A. Audu, Azuka P.
243 Okwuraiwe and Aaron O. Aboderin 2016. Occult hepatitis B virus infection in preiously
244 screened blood donors in ile-ife, Nigeria: implication for blood transfusion and stem and
245 cell transplantation. Virology journal 2016 13:76
- 246 11. Azimi H, Vaezjalali M 2016. Hepatitis B Core Antibody Immunoglobulin M in Blood
247 Donors with a History of Hepatitis B Virus Infection, *Arch Clin Infect Dis*.11 (3):e38232.
- 248 12. Lin, H., Zhao, H., Tang, X., Hu, W., Jiang, N., Zhu, S., and Huang C 2016. Serological
249 Patterns and Molecular Characterization of Occult Hepatitis B Virus Infection among
250 Blood Donors. *Hepat Mon*. 16(10):e40492
251
- 252 13. Makroo Rn, Mohit Chowdhry, Aakanksha Bhatia, Bhauna Arora, Rosamma NL 2012.
253 Hepatitis B core antibody testing in Indian blood donors; A double-edged sword. Asian
254 journal of transfusion science. Vol 6:pg10-13
- 255 14. Yotsuyanagi H, Yasuda K, Moriya K, Shintani Y, Fujie H, Tsutsumi T 2001. Frequent
256 presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors.
257 *Transfusion* vol41:1093-9.
- 258 15. Japhet OM, Adesina OA, Donbraye E, Adewumi MO. 2011. Hepatitis B core IgM
259 antibody (anti-HBcIgM) among hepatitis B surface antigen (HBsAg) negative blood
260 donors in Nigeria. *Virol J* 8:513.

- 261 16. Jeremiah ZA, Idris H, Ajayi BB, Ezimah AC, Malah MB, Baba MM 2011. Isolated anti-
262 HBc-IgM antibody among blood donors in the semi-arid region of Nigeria. Hum
263 Antibodies. 20(3-4):77-82.
264
- 265 17. Odaibo GN, Ola SO, Olaleye OD 2013. Hepatitis B virus DNA in patients with HBsAg
266 in south western Nigeria. J Med Virol. 2013 Feb; 85(2):214-8.
- 267 18. Omotola CA, Onoja BA, Thomas T 2017. High Rate of Hepatitis B Virus Surface
268 Antigenemia Among People Living with HIV/AIDS in Kakuri, Kaduna State, North
269 West Nigeria. Viral Immunol. 2017 Sep; 30(7):516-521.
270
- 271 19. Oluyinka OO, Tong HV, Bui Tien S, Fagbami AH, Adekanle O, Ojurongbe O, et al. 2015.
272 Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus
273 Transmission Risks. PLoS ONE 10(7): e0131912
274
- 275 20. Ogunfemi MK, Olawumi HO, Olokoba AB, Kagu MB, Biliaminu SA, Durowade KA,
276 Durotoye IA, Shittu AO 2017. Prevalence of antibody to hepatitis B core antigen among
277 hepatitis B surface antigen-negative blood donors in Ilorin, Nigeria: A cross-sectional
278 study. Malawi Med J. 2017 Mar; 29(1):32-36.
279
- 280 21. Akinbami AA, Oshinaike OO, Dosunmu OA, Adeyemo TA, Adediran A, Akanmu S,
281 Wright KO, Ilori S, Aile K 2012. Seroprevalence of hepatitis B e antigen (HBe antigen)
282 and B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B surface
283 antigen positive blood donors at a Tertiary Centre in Nigeria. BMC Research Notes
284 5:167.
285
- 286 22. Sosa-Jurado, F., Rosas-Murrieta, N. H., Guzman-Flores, B., Zempoaltécalt, C. P.,
287 Sanchez Torres, A. P, Rosete, L. R., Bernal-Soto, B., Marquez-Dominguez, L.,
288 Melendez-Mena, D., Mendoza Torres, M .A., Lopez Delgado, M.T., Reyes-Leyva, J.,
289 Vallejo-Ruiz, V., and Santos-Lopez G 2016. Prevalence of Serologic Hepatitis B Markers
290 in Blood Donors from Puebla, Mexico: The Association of Relatively High Levels of
291 Anti-Core Antibodies with the Detection of Surface Antigen and Genomic DNA. Hepat
292 Mon. 16(6):e36942.

- 293
- 294 23. Castelain, S., Descamps, V., Brochot, E., Helle, F., Duverlie, G., Nguyen-Khac, E.,
295 François, C 2017. High association of T1858-G1896 precore mutations with impaired
296 base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically
297 infected patients. *Arch Virol* (2017) 162: 1913.
- 298 24. Alagiozian-Angelova V., Alagiozian D., Antonov K., Krustev Z 1998. Clinical
299 significance of serum HBeAg and HBV-DNA-specific values of virus replication in
300 chronic hepatitis-B virus infection. *Folia Med (Plovdiv)*. 1998; 40(4):34-41.
- 301
- 302 25. Liang TJ, Ghany M 2002. Hepatitis B e antigen—the dangerous endgame of hepatitis B. *N*
303 *Engl J Med*. 347:208–210.
- 304
- 305 26. Kao JH 2008. Diagnosis of hepatitis B virus infection through serological and virological
306 markers. *Expert Rev Gastroenterol Hepatol*. 2(4):553-62.
- 307
- 308 27. Yu Y, Wan P, Cao Y, Zhang W, Chen J, Tan L, Wang Y, Sun Z, Zhang Q, Wan Y, Zhu
309 Y, Liu F, Wu K, Liu Y, Wu J 2017. Hepatitis B Virus e Antigen Activates the Suppressor
310 of Cytokine Signaling 2 to Repress Interferon Action. *Sci Rep*. 7(1):1729.
- 311 28. Zheng H, Cui FQ, Wang FZ, Huang LF, Shao XP, Du JF, Li J, Zhou Y, Zheng HZ, Zhuo
312 JT, Zeng XX, Zhang GM, Miao N, Sun XJ, Liang XF, Luo HM 2017. The epidemiology
313 of hepatitis B virus infection in women of reproductive age in highly endemic areas in
314 China. *J Viral Hepat*. Aug 23. doi: 10.1111/jvh.12757.
- 315
- 316 29. Mulrooney-Cousins P. M., Michalak T. I. 2007. Persistent occult hepatitis B virus
317 infection: experimental findings and clinical implications. *World J Gastroenterol*.
318 13(43):5682–6.
- 319 30. de la Fuente RA, Gutierrez ML, Garcia-Samaniego J, Fernandez-Rodriguez C, Lledo JL,
320 Castellano G 2011. Pathogenesis of occult chronic hepatitis B virus infection. *World J*
321 *Gastroenterology* 17(12):1543–8.
- 322

- 323 31. Larrubia JR.2011. Occult hepatitis B virus infection: a complex entity with relevant
324 clinical implications. *World J Gastroenterol*. 17(12):1529–30.

325

326 .

327